Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance

Adaptive Biotechnologies Corp

2025-Q1 EPS reported -$0.20 revenue$52,443,000

Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.
Net loss narrowed to $29.8M from $47.5M; adjusted EBITDA loss $12.7M from $28.2M.
Raises FY 2025 MRD revenue guidance to $180-190M (from $175-185M); lowers cash burn target to $50-60M.
Expanded Medicare coverage for clonoSEQ in mantle cell lymphoma recurrence monitoring.
Cash, equivalents, and marketable securities $232.8M at March 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.